BioCentury
ARTICLE | Financial News

Innate Pharma raises EUR 50 million in private placement

June 27, 2014 11:50 PM UTC

Innate Pharma S.A. (Euronext:IPH) raised EUR 50 million ($68 million) through the sale of 6.3 million shares at EUR 8 in a private placement to institutional investors. The price is a 14% discount to Innate's close of EUR 9.32 on June 18, before the company proposed the offering.

Innate's lirilumab ( BMS-986015; IPH2102) is in Phase II testing as maintenance treatment for acute myelogenous leukemia (AML). Bristol-Myers Squibb Co. (NYSE:BMY) has exclusive, worldwide rights to the human anti- killer cell immunoglobulin-like receptors (KIR) mAb. ...